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SUMMARY
Type 2 diabetes and other noncommunicable diseases are a growing public health challenge 
globally. An estimated 285 million people, corresponding to 6.4% of the world’s adult population, 
has diabetes, which is expected to reach 552 million by the International Diabetes Federation in 
2030. A much larger segment of the world’s population, approximating 79 million individuals in 
the USA alone, has prediabetes. Globally, a relatively small percentage of those with diabetes or 
prediabetes are diagnosed with the potential for developing chronic complications. To address this 
epidemic, governments, in concert with the private sector, need to set policies that promote 
healthy nutritional and agricultural policies, favor modifications in the environment that encourage 
greater physical activity and make prevention affordable for all citizens at high risk. The public 
health sector has the charge of translating evidence-based findings into practical, accessible and 
cost-effective programs and monitoring the process to continuously improve prevention initiatives. 
The clinical sector has the formidable challenge of screening and identifying those at high risk and 
referring them to accredited intervention programs. There is a need to explore additional cost-
effective interventions that are customized to meet individual needs that can be offered at the 
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community and clinical levels. Thus, all three sectors, government, public health and clinical, each 
have a critical role in this process and by working in a partnership, ought to create the necessary 
synergies essential for making substantial forays in the prevention of Type 2 diabetes.
As Type 2 diabetes and other noncommunicable diseases (NCD) are a growing public health 
challenge globally, the World Economic Forum foresees a severe disaster impacting global 
economic growth [1,2]. An estimated 285 million people, corresponding to 6.4% of the 
world’s adult population has diabetes, with the prevalence varying from 10.2% in the 
western Pacific to 3.8% in the African region. This is expected to reach 552 million by 2030, 
corresponding to 7.8% of the adult population with the African region expected to 
experience the greatest increase. In total, 70% of cases occur in low- and middle-income 
countries (LMIC) resulting from consumption of high-calorie foods as well as decreasing 
physical activity. Diabetes in LMICs affects an increasing number of younger individuals 
especially in their productive years.
Dysglycemia characterized by glucose levels not meeting conventional criteria for diabetes 
but yet higher than normal constitutes the population with prediabetes [3,4], a condition that 
may exist for many years before Type 2 diabetes occurs. In the USA, approximately a 
quarter (and as high as 50–80% in LMICs) of individuals with diabetes and only 7% of 
those with prediabetes are diagnosed with the potential for developing chronic complications 
due to delayed detection and timely diagnosis of prediabetes [5,101]. A substantial number 
of individuals (up to 70%) with prediabetes may develop diabetes in subsequent years [6], 
with an average annual risk approximating 5–10% compared with well below 1% in 
normoglycemic individuals [7]. Furthermore, prediabetes is associated with a 10–40% 
increased risk of cardiovascular complications, as well as stroke and microvascular disease 
[8,9]. Early recognition of prediabetes in high-risk individuals is, therefore, crucial as 
lifestyle modification in particular, as well as medication, have been shown to be effective in 
reducing the progression to diabetes in seminal studies conducted across diverse cultures [8–
11]. Details of the various diabetes prevention programs have been recently summarized 
including publications describing sustainability of their effects [12].
This paper will review the definition of prediabetes and surrounding controversy, 
subsequently consider current community interventions for the prevention of Type 2 
diabetes and then describe global healthcare policies and formulate recommendations for 
further efforts at prevention.
Definition of prediabetes
American Diabetes Association
The American Diabetes Association (ADA) [2,13–15] clinical guidelines define prediabetes 
as either impaired fasting glucose (IFG; fasting plasma glucose [FPG] = 5.6–6.9 mmol/l) or 
impaired glucose tolerance (IGT; glucose = 7.8–11.1 mmol/l during a 2-h oral glucose 
tolerance test [OGTT]). FPG is the preferred test for screening as it is convenient and the 
receiver operator curve (ROC) analysis indicates that a FPG cut-point of 5.6 mmol/l gives 
the best combination of sensitivity and specificity for predicting future diabetes. Diagnosis 
of diabetes is based on a FPG of ≥7.0 mmol/l and/or a postchallenge glucose (120 min) level 
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of ≥11.1 mmol/l, or a casual plasma glucose of ≥11.1 mmol/l in the presence of symptoms 
with an abnormal result requiring repeat measurement in an asymptomatic individual [12].
The ADA recommends glycated hemoglobin (HbA1c) as another screening option for 
prediabetes [14,15]. A HbA1c level between 5.7 and 6.4% identifies those at risk for diabetes 
whereas those with a level of 6.0–6.5% are at particularly high risk. Diabetes is diagnosed 
by a HbA1c value ≥6.5%, as most epidemiological studies and recently in the DETECT-2 
analysis [16] indicated that there is an increased risk for retinopathy with HbA1c levels 
approximating 6.5% (comparable to the risk for corresponding FPG [≥7.0 mmol/l] and 2 h 
plasma glucose [≥11.1 mmol/l]).
WHO
WHO [17,102] has recommended that the diagnostic cut-point for IFG should be maintained 
at 6.1 mmol/l [2] (vs 5.6 mmol/l suggested by the Expert Committee [10] and the ADA 
[15]). This decision was based on concerns about the substantial increase in IFG prevalence 
by lowering the cut-point to 5.6 mmol/l and the associated impact on individuals and 
healthcare systems [18]. WHO advocated maintaining established IGT criteria with the 
recommendation that individuals with IFG undergo an OGTT to exclude IGT or diabetes.
The WHO recommended HbA1c >6.5% as a diagnostic threshold for diabetes whereas a 
lower value does not exclude diabetes using glucose-based criteria. The WHO also indicated 
that there is currently ‘insufficient evidence’ to make any formal recommendation on the 
interpretation of HbA1c levels below 6.5% [17].
Caveats of current definitions
The early identification of prediabetes permits intensive management to delay the 
progression to diabetes and to potentially prevent the development of chronic complications 
[19]. However, there is a lack of consensus as to which screening procedure is most 
appropriate [20]. For decades, the diagnosis of prediabetes has been based upon FPG and/or 
2-h glucose levels after an OGTT. Advantages of the FPG include its ease and 
inexpensiveness with universally available automated instruments. Similarly, OGTT serves 
as another option for diagnosing prediabetes, the 2-h glucose level being a better predictor of 
cardiovascular morbidity and mortality than the FPG [21,22]. Nevertheless, both glucose-
based measurements are subject to methodological limitations, particularly in terms of 
biologic and analytic variability. Moreover, OGTT (which is time consuming and 
expensive) has relatively poor reproducibility [21,22].
HbA1c reflecting average plasma glucose over the previous 8–12 weeks, when compared 
with glucose testing, avoids the problem of day-to-day variability of glucose values and the 
need to fast. Moreover, HbA1c measurement also has superior methodological attributes 
when compared with blood glucose, such as minimal intraindividual variability [21,22]. 
Therefore, as standardization procedures have improved, the availability of HbA1c as a 
single, nonfasting blood test could facilitate successful population-level screening programs, 
as has also been recently demonstrated by the WEQAYA study and by others [23,24].
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On the other hand, the use of HbA1c implies that stringent quality assurance tests are in 
place and assays are standardized to criteria aligned with international reference values and 
that there are no conditions present that preclude its accurate measurement. Indeed, HbA1c 
may be affected by a variety of genetic, hematological and illness-related factors, with 
hemoglobinopathies being the most common, as well as certain anemias and disorders 
associated with red cell turnover such as malaria [17–20,25,26,102]. Preliminary data from 
the FIN-D2D study also suggest that the HbA1c value is age dependent. Thus, in healthy 
populations screened with OGTT, in older individuals compared with younger ones, a 
particular HbA1c value implied slightly lower fasting glucose but relatively higher 2-h 
glucose levels, a finding that needs to be verified in different populations [27]. In addition, 
limited availability and cost in many countries may not allow HbA1c testing as a practical 
option for screening purposes.
Several studies indicate that the HbA1c range of 5.7–6.4% permits adequate screening for 
prediabetes and is an excellent predictor of risk for progression to diabetes and/or 
development of cardiovascular disease [19–21,28,29]. However, the use of HbA1c as a 
screening test remains controversial [30]. Many individuals diagnosed with prediabetes 
based on glucose testing, in particular IFG, are reclassified as normoglycemic when a HbA1c 
determination is used. Therefore, Mann et al. [31] and others [32–34] stressed that the use of 
HbA1c alone, in part due to lesser sensitivity, might overlook a large number of individuals 
with prediabetes. Alternatively, the use of HbA1c may also lead to the reclassification of a 
considerable number of subjects without IFG to having prediabetes [31].
As the evolution to diabetes follows a continuum [35], risk of diabetes and/or cardiovascular 
complications could extend below the current recommended threshold criteria for diagnosis. 
Contradictory data, in particular with regard to the sensitivity of HbA1c, limit the ability to 
accurately diagnose prediabetes. This, in conjunction with divergent global definitions of 
prediabetes, infuses discordance in healthcare policy with regard to precisely defining the 
appropriate target population who will benefit most from prevention strategies. Threshold 
criteria for defining risk with greater accurately should be based on outcomes from future 
epidemiological studies. Glucose and HbA1c criteria for diagnosing dysglycemic conditions 
appear to be discrepant as they may be defining different populations at risk for progression 
to diabetes. Therefore, the combination of FPG and HbA1c may represent a more adequate 
strategy for identifying individuals at risk [36,37].
Community interventions & policies for the prevention of Type 2 diabetes
Healthcare systems are generally focused on care and not prevention. Most European 
countries have national health insurances that finance care after an International 
Classification of Diseases 10/11 diagnosis has been made. Preventing Type 2 diabetes 
requires complementary clinical and public health strategies at the community level [38,39]. 
The clinical sector plays a significant role in identifying risk status, referring individuals at 
high risk to community-based lifestyle programs, providing nutrition counseling, prescribing 
medication when required and treating those who develop diabetes. On the other hand, the 
public health sector has a major role in monitoring diabetes risk, mobilizing partnerships to 
establish diabetes prevention services for individuals at high risk and assuring the quality of 
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these programs. Furthermore, the public health sector needs to examine policies that support 
risk reduction by facilitating lifestyle modification and changes to community environments 
that make it easier to practice healthy behaviors. The synergies of clinical and community 
public health sectors are represented in Figure 1.
As progression from low to high risk for diabetes occurs as a continuous process, effective 
interventions along this continuum are theoretically needed. The evidence for diabetes 
prevention, however, mostly involve those at high risk (i.e., with prediabetes [40]) and as 
large-scale diabetes prevention programs have focused on the latter, it has not been 
established whether intervening in lower risk individuals will be equally effective.
Several translational research studies conducted in real-world settings have implemented 
modified versions of the lifestyle intervention from clinical trials, such as the US Diabetes 
Prevention Program (US DPP) [8] and Finnish Diabetes Prevention Program [11]. The 
structured lifestyle intervention includes an initial series of sessions (usually delivered 
weekly) that help participants learn skills to reduce caloric intake, increase physical activity 
and problem solve to achieve weight loss, which is followed by a series of maintenance 
sessions (usually delivered monthly).
A major focus of translational research is how to best utilize limited resources for delivering 
lifestyle intervention to significantly decrease the incidence of and health costs associated 
with Type 2 diabetes. Uusitupa et al. summarized published implementation studies 
conducted in various countries with different designs and outcome measures and described 
prevention activities in Finland [41]. The Finnish program, demonstrated that it was possible 
to prevent Type 2 diabetes in real life, primary healthcare settings [41,42]. Methods for 
recruiting high-risk subjects were simple and easy to use. Lifestyle changes and risk 
reduction of diabetes required a modest number of visits to health centers or occupational 
healthcare outpatient clinics. Moderate weight loss in very high-risk individuals was 
especially effective in reducing the risk of diabetes and reduction of cardiovascular risk [42]. 
The Life! Program in Australia, is based on the successful exchange of results from 
randomized trials and implementation trials in Finland and Australia. The latter represents 
yet another example of translating prevention research into a large-scale intervention in 
adults over 50 years of age at high risk of developing diabetes using community-based 
facilitators [43,44].
Ali et al. have recently published a systematic review and meta-analysis of 28 US translation 
studies based on the US DPP demonstrating that 12 months subsequent to the intervention, 
there was an average weight loss of 4% from baseline, which was similar regardless of 
whether the intervention was delivered by a healthcare professional or lay educator [45]. 
Furthermore, with each additional lifestyle session attended, weight loss increased by 
0.26%.
In addition to demonstrating durability of treatment effect, it is also critical that healthcare 
costs associated with community-based lifestyle intervention for preventing Type 2 diabetes 
are assessed. Evidence from a simulation model projecting the costs and benefits of a 
nationwide community-based lifestyle intervention suggest that such a program would 
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represent an efficient use of healthcare resources [46]. Despite considerable initial 
investment, within 25 years, the program would prevent or delay approximately 885,000 
cases of Type 2 diabetes in the USA and produce savings of US$5.7 billion nationwide. 
Although cost savings would occur in both younger and older individuals, greater health and 
economic gains would be achieved if directed at those under the age of 65 years.
Reduction in the incidence of Type 2 diabetes on a population level requires collaboration 
among community-based organizations, insurance payers, healthcare and public health 
professionals, academia and others. In 2010, the US Congress authorized the CDC to 
establish the National Diabetes Prevention Program (National DPP) to translate and 
systematically scale the US DPP for individuals at high risk. The National DPP brings 
together the groups listed above and unifies delivery of proven lifestyle change programs in 
communities throughout the country. The National DPP consists of four components, as 
outlined below.
Training
The CDC established the Diabetes Training and Technical Assistance Center (DTTAC) at 
Emory University (Atlanta, GA, USA) to help increase the work force by providing training 
to lifestyle coaches and those who train lifestyle coaches. There are other organizations, 
such as the Young Men’s Christian Association (YMCA), that provide training so DTTAC 
also serves to coordinate training functions [103].
Program recognition
The CDC Diabetes Prevention Recognition Program (DPRP) [104] assures program quality, 
consistency, provides a registry of recognized programs and implements standardized 
reporting on performance of recognized programs.
Intervention sites
The YMCA and UnitedHealth Group (UHG) are the first to participate in the National DPP 
and are collaborating on instituting community-based prevention programs in which the 
YMCA delivers the lifestyle change program while the UHG provides third-party 
reimbursement for its beneficiaries. This is a new payment model in which an insurer 
reimburses a community-based organization based on performance. With implementation of 
the DPRP, more organizations are involved in program delivery and reimbursement.
Health marketing
Participant engagement and healthcare provider referrals are important for program success. 
CDC and others, such as the Diabetes Prevention and Control Alliance, are testing various 
marketing strategies to enhance program participation.
Implementing lifestyle change programs to prevent diabetes is not without challenges. In 
order to achieve the desired health outcomes on a large scale, the areas discussed in the 
following sections are among those that need to be addressed.
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Identification of individuals at increased risk—The preponderance of evidence for 
diabetes prevention is derived from initiatives focusing on those at increased risk (i.e., with 
prediabetes) for diabetes [47] in which the target population was identified based on risk 
stratification and outcomes were measurable. Measuring risk, however, is more challenging 
when defined at the population level, and therefore validated instruments assessing risk 
gradients are required [48,49]. An example is a questionnaire based on the FINDRISK 
studies that has been implemented in several countries [49]. A two-step screening procedure 
starting with the FINDRISK questionnaire followed by a glucose test for those identified at 
increased risk might be the most cost-effective approach [49,50].
Standardization of lifestyle intervention—Policy development requires utilization of 
evidence-based, standardized lifestyle intervention recommendations that are customized to 
reflect cultural and individual circumstances. Furthermore, diabetes prevention is strongly 
related to an increase in physical activity and a reduction in fat and increased fiber 
consumption. Standardized recommendations for diabetes prevention can therefore be 
related to physiologically based core goals and increased effectiveness of policy 
development. This is exemplified by The European IMAGE project that has pioneered 
guidelines with a practice toolkit [51,52], as has NICE [53]. The National DPP is achieving 
this through the DPRP, which requires a standardized curriculum that recognized 
organizations can obtain gratis from the DPRP website. Alternatively, curricula can be 
evaluated to ensure that required content areas and program length are met.
Education & training of personnel—Implementation of diabetes prevention initiatives, 
although not requiring medical specialists per se, requires skilled personnel. There is a 
growing need for the development and implementation of training curricula for prevention 
personnel so that they may effectively instruct individuals at risk in sustained lifestyle 
change [54]. Curricula have been developed in Europe [55] and the USA [105], although it 
will take time until a critical mass has been trained. The number of skilled personnel will 
depend on the organizational structure in which they will work.
Monitoring—The public health sector can play an important role in continuous evaluation 
and monitoring to ensure successful implementation of diabetes prevention programs. 
Furthermore, this is vital for quality assurance and benchmarking of standardized 
procedures. Scientific outcome evaluation indicators and measurement recommendations 
(e.g., body weight, waist circumference, HbA1c and total energy intake) have been 
developed to monitor the effectiveness and efficiency of the programs [56]. Recent 
experience demonstrates that monitoring alone, as a function of quality management, is a 
driver for increasing the quality of intervention programs [57]. The CDC DPRP, as part of 
the National DPP, serves this monitoring function for diabetes prevention programs in the 
USA.
In addition to targeting high-risk individuals through lifestyle change programs in the 
community, general population level policy requires implementation of evidence and 
practice-based policies in modifying the environment and infrastructure to improve 
nutrition, decrease weight, increase physical activity and facilitate tobacco cessation. In 
some places, complementary strategies targeting those at high risk and the general 
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population is not occurring and in some cases, only one segment of a population is involved. 
Some countries assign responsibilities for diabetes prevention to agricultural ministries in 
which activities are often restricted to aspects of food production, and therefore do not 
establish a prevention initiative. As LMICs often lack the financial resources to manage 
diabetes, they therefore may only develop strategies for lifestyle education as well as 
physical activity in schools [48]. Effective policies for food procurement and production, as 
well as strategies promoting healthy lifestyles in children, have important potential to 
contribute to diabetes prevention and should continue to be examined.
Global health policy & perspectives from the ground
As previously described, screening procedures for diabetes and prediabetes are fraught with 
complexity and inaccuracy, often making diagnosis difficult except in the most obvious 
circumstances. Nonetheless, based on fasting glucose or HbA1c levels, 35% of US adults 
aged 20 years or older were estimated to have prediabetes in 2005–2008 (50% of those aged 
65 years or older). Thus, 79 million Americans aged 20 years or older are estimated to have 
prediabetes in 2010 [106].
Translating prevention initiatives to policy
Although the US DPP research study in 2002 [8], upon which translational models have 
been developed (see above), demonstrated the inarguable benefit of lifestyle modification in 
preventing the progression from IFG and/or IGT to Type 2 diabetes, the majority of the US 
population with prediabetes remains undiagnosed and untreated [6,58]. Although the reasons 
for this are unknown, national policies, such as public and provider education programs, 
need to be developed, especially as dissemination of national guidelines are generally 
ineffective in changing clinical practice [59]. There exists an urgent need to translate 
evidence from prevention initiatives into policy and affordable, feasible programs [59,60] in 
order to detect individuals at risk with appropriate referral to lifestyle intervention programs. 
This is particularly essential because once individuals with prediabetes progress to diabetes, 
management of the latter remains inadequate. In the USA where US$132 billion is spent 
annually on diabetes care, simultaneous control of glucose levels, blood pressure and lipid 
levels is achieved in less than 10% of individuals with diabetes [61,62]. Furthermore, 
effective prevention strategies should constitute a major approach particularly in view of the 
lengthy preclinical phase characterizing the transition from prediabetes to Type 2 diabetes 
that thereby provide an extended window for intervention [62].
Examining current public health policies with regard to diabetes prevention is vital, given 
the enormous economic and social burdens diabetes creates, as it most often affects 
individuals in the prime of their lives, reducing their productivity aside from driving direct 
healthcare expenditures. It has been estimated that the proportion of cardiovascular disease 
attributable to diabetes has increased over the past 50 years, highlighting the need for 
increased efforts at prevention and aggressively addressing cardiovascular risk factors 
among those with diabetes [63]. Indirect costs, such as decreased income, premature 
retirement and unemployment, can be even more costly than the direct expenditures 
associated with the condition [64]. Indeed, global costs of diabetes approximated US$500 
billion in 2010 and are anticipated to reach US$745 billion in 2030.
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Diabetes prevention & global health policies
Effective global public health policies are crucial for addressing diabetes and other NCDs, 
especially as they account for the preponderance of deaths worldwide and constitute a ‘slow-
motion disaster’ [65]. Although NCDs are by definition noninfectious, Type 2 diabetes has 
also been elegantly characterized as an infectious disease by Matthews and Matthews in 
their 2010 Banting Memorial Lecture [66], and as such might be ‘eradicated’ in the same 
fashion. Calorie excess serves as a transmissible agent, propagated by inadequate food 
labeling and poorly regulated advertising vectors embedded within a reservoir of fast-food 
outlets providing cheap calories. Sedentary lifestyles provide a predisposing toxic milieu in 
which limited physical activity works in concert with consumption of excess calories 
leading to weight gain, obesity and increased risk of diabetes [66]. Analogous to an 
infectious pandemic, breaking the cycle of transmission in the case of diabetes must involve 
political will and decisive legislation and support by the medical community [66].
Whether diabetes is characterized as communicable or noncommunicable, both perspectives 
commonly point to the critical need for action. Thus, the increasing toll associated with 
NCDs led to a 2-day high-level meeting of the UN General Assembly in September 2011, 
creating an awareness of the enormity of the global problem. This meeting was constituted 
by unprecedented participation of global leadership from Heads of State, the WHO, 
nongovernmental organizations and member states. This was a very positive step for NCDs 
as well as global collaboration as the high-level meeting resulted in a political declaration 
calling for collaborative effort to reduce risk factors and strengthen national policies to 
prevent and control NCDs. While recognizing the NCD epidemic, the conference did not 
elucidate deadlines or targets or a system of accountability and neither was funding allocated 
for treatment or prevention. However, targets are under discussion and will be released 
before the end of 2012. Although the UN Summit did not address all of the expectations, it 
provided diabetes and NCDs with a global platform [67]. It was left to governments to 
“customize the implementation” of their commitments.
The International Diabetes Federation has been instrumental in providing an overall 
framework representing the global diabetes community [67]. In addition to improving the 
health outcomes of individuals with diabetes and addressing discrimination of individuals 
with diabetes, prevention of Type 2 diabetes constitutes a key objective of the plan. 
Prevention and treatment are not considered to be alternative options as they are both 
equally important. The UN and its agencies are advised to work with national governments 
to reorient health systems to a preventative model addressing health in all polices, such as 
urban design and housing, workplace design, food production, healthy nutrition and physical 
activity. Concerted action at the international and national policy levels will, therefore, be 
required to advance science-driven health initiatives in these areas and translation into 
practice [68,69], while meticulously avoiding overzealous and well-meaning policy 
initiatives of hitherto unproven benefit. These recommendations are congruous with the 
three pivotal levers for change described by Yach et al. [70]:
■ Raising the profile of chronic disease in the mind and on the agenda of policy 
makers;
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■ Providing policy makers with evidence to support the case for prevention;
■ Advocating the need for widespread health system change.
These should also include entire government systems beyond healthcare and involve global 
corporations and labor unions, as well as nongovernmental organizations. Furthermore, 
chronic disease alliances need to be formulated including industry and academia 
[60,71,107], such as the Oxford Health Alliance, the Global Alliance for Chronic Diseases 
and the Global Partnerships Forum. Political commitment and action are critically required 
at high global and national levels particularly as prevention of diabetes and its complications 
are dramatically underfunded and as major gaps exist between findings from clinical trials 
and their implementation in clinical and public health practice [71].
Research funding agencies tend to favor medical and surgical solutions over health 
promotion and health systems interventions and policies [71]. Furthermore, although 
research has shown that improving diets has greater potential to improve quality-adjusted 
life years, reduce morality and medical costs than medications, funding favors medications 
[72,107]. The WHO has called for research into prevention and intervention implementation 
in addition to integrating prevention efforts in national programs and engaging government 
and corporate sectors [72,73]. The WHO priority areas for diabetes prevention, control and 
research include community-based primary prevention models focusing on nutrition, 
physical activity, urbanization and transportation [73]. Indeed, multifaceted approaches to 
diabetes management have been effective in secondary prevention but a similar response to 
primary prevention is lacking, thereby “exposing primary prevention as the weak link in the 
public health response to diabetes” [74]. Detecting prediabetes and undiagnosed diabetes 
may be the link and stimulus to reorient systems toward preventive care. Hence, if efforts 
are not made in primary prevention, the increasing rate of diabetes will obscure or negate 
achieved successes in secondary prevention [74].
A major review by Popkin and colleagues states that improving global diets is ‘imperative’ 
to prevent and control obesity, diabetes and other NCDs [75]. Realistic policy interventions 
must be directed at making healthy choices easier rather than coercing individuals to make 
healthy choices [76]. Taxation is one option to change health behavior [77] but may not be a 
popular approach [78]. The pricing and availability of healthy foods needs attention. Pricing 
is best addressed across all major food categories, and supported by the need for better 
agricultural and food policies to address diabetes [79]. Strong industry collaboration has 
made significant progress on several key areas, such as reformulating to reduce sugar, 
innovating smaller package sizes, labeling calories and sugar, restricting marketing to 
children, withdrawing full-calorie sodas from schools and investment in activity programs, 
such as the Healthy Weight Commitment Foundation and the International Food and 
Beverage Alliance [80].
Focusing on improving health through modifying the environment for the entire population 
is more desirable than health education or promotion campaigns. Policies to align 
agricultural policy with nutrition and health goals will allow the agriculture and food 
industries, both with great influence on health, to contribute to the prevention and control of 
diabetes and other NCDs [80,81].
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Ground level proposals for the primary prevention of diabetes
While confronting NCDs in general and diabetes in particular at the highest levels of 
national and international governmental agencies is absolutely necessary to promote shifts in 
healthcare delivery, this process will clearly take time. Since the crisis is well upon us, 
current strategies involving community resources described above are crucial and need 
further expansion. Narayan et al. has stated that, “the fight against diseases is global and … 
solutions can emerge from anywhere” [68]. So, what additional options can be undertaken to 
identify and refer individuals at risk for progression to diabetes? Evidence-based approaches 
involving health promotion, obesity prevention and policies to improve the behaviors and 
environment on a population basis need to be reinforced with the identification and referral 
of the almost one-third of adults with prediabetes to effective lifestyle change programs 
[74]. Investment in research to better understand what kinds of policies at environmental 
levels work to reduce obesity and diabetes risk is needed. Currently, few interventions tested 
at the population or environmental levels are proven to be beneficial.
Novel approaches to training are required to meet the global demands of caring for patients 
with chronic conditions [82]. The healthcare system needs to transition from a reactive to a 
proactive perspective with regard to prevention and approach this issue on a population basis 
beyond caring for the individual patient [82]. Healthcare workers will, therefore, need to 
develop a broad approach to patient care considering the entire continuum from community 
prevention to palliative care [82]. Establishing new core competencies will require 
restructuring of training to include knowledge, skills and abilities designed to prepare 21st 
century health workers to address current challenges [82].
Box 1
Ground level proposals for the primary prevention of diabetes
■ Broaden emphasis on prevention in medical and graduate training and extend to 
allied healthcare providers.
■ Integration of graduate programs in public health (MPH) with medical and allied 
healthcare curricula with reference to prevention.
■ Medical and scientific societies – especially primary care – need to embrace 
platforms for prevention.
■ Continuing medical education offerings should include prevention modules (e.g., 
webinars, scientific meetings and so on).
■ Delivery of community-based prevention programs that are supported by third-
party reimbursement with referrals from healthcare professionals.
■ Increase dialog between practice managers and health insurers for reimbursement 
and incentivizing visits for primary prevention and nutrition.
■ Community screening for prediabetes/diabetes in high-risk populations.
■ Establish hospital and academically based prevention and treatment referral 
programs.
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■ Promote collaboration between academic medical centers with local/regional 
public health agencies.
■ Public outreach seminars on diabetes prevention.
Ground level proposals, for primary prevention, listed in Box 1, complement community 
programs such as the National DPP. A limiting factor in prevention is the inability to 
recognize metabolic disorders early in their course, because these tend to be subtle and often 
are not considered given the significant challenges of primary care practitioners in managing 
ever-increasing patient volumes in the context of decreased reimbursement. Providing 
adequate compensation for prevention visits during which individuals at high risk would be 
advised to engage in lifestyle modification and are provided referrals for nutritional 
counseling and community-based programs is essential and would help reduce ‘clinical 
inertia’. The latter appears to be increasingly undertaken by third-party insurers. The 
development of accredited, cost-effective hospital-based initiatives should be encouraged to 
supplement prevention programs in the community. The CDC DPRP recognizes any 
organization that meets the program standards. All healthcare professionals, regardless of 
specialty, should be instructed to refer individuals at risk to their physician for further 
evaluation and referral.
Continuing medical education courses, utilizing web-based and other formats, as well as 
satellite symposia held at scientific congresses, should be focused particularly on 
pediatricians, primary care and family physicians. Clinical case presentations should be 
utilized to illustrate screening, diagnosis and treatment principles. Given the enormous 
population at risk, community-based strategies involving local health departments should 
also be considered. The overwhelming burden of screening and treatment may, therefore, be 
mitigated and achieved by integrating diabetes prevention programs within extant hospitals 
or community clinics garnered with necessary training and duly recognized.
As current medical school curricula offer basic public health principles, perhaps because it 
tends not to adequately focus on chronic disease management [83], consideration should be 
given to the development of more extensive prevention modules in collaboration with public 
health faculty. This should enhance life-long awareness of the importance of prevention and 
may also provide motivation to pursue a career in public health practice and research.
Conclusion & future perspective
It is the responsibility of the medical community to reach out to the broader public raising 
awareness of the current epidemic and offering basic instruction in the importance of 
lifestyle modification while encouraging referral for those at risk. Governments, in concert 
with the private sector, need to set policies that promote healthy nutritional and agricultural 
policies, favor modifications in the environment that encourage greater physical activity and 
make prevention affordable for all citizens at high risk. The public health sector has the 
charge of translating evidence-based findings into practical, accessible and cost-effective 
programs and monitoring the process to continuously improve prevention initiatives. The 
clinical sector has the formidable challenge of screening and identifying those at high risk 
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and referring to accredited intervention programs. There is a need to explore additional cost-
effective interventions that are customized to meet individual needs that can be offered at 
the community and clinical levels. Thus, all three sectors, government, public health and 
clinical, each have a critical role in this process and by working as a partnership, ought to 
create the necessary synergies essential for making substantial forays in the prevention of 
diabetes.
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Practice Points
■ Prediabetes, characterized by an extended period of increasing dysglycemia, may 
exist for many years before Type 2 diabetes is diagnosed.
■ Prediabetes is defined globally by glucose criteria, although fasting threshold 
levels differ in accordance with American Diabetes Association (ADA) or WHO 
recommendations.
■ HbA1c threshold ≥6.5% has been adopted globally for defining diabetes. 
Prediabetes is defined by the ADA, but not the WHO, with HbA1c levels 5.7–6.4%, 
the range between 6.0–6.4% conferring high-risk status. Contradictory data with 
regard to sensitivity may indicate that the ability to accurately diagnose prediabetes 
is limited.
■ HbA1c may be affected by genetic, hematological and illness-related factors that 
may limit its accuracy.
■ It is essential to identify individuals at high risk for developing Type 2 diabetes 
during this period to potentially obviate the development of diabetes and forestall the 
development of complications that may occur with prediabetes as well as with 
diabetes.
■ Evidence-based clinical trials in high-risk individuals have proven the benefit of 
lifestyle intervention consisting of weight reduction, dietary modification and 
exercise, which is greater than with pharmacologic treatment, in dramatically 
reducing the evolution to diabetes.
■ Translational research studies implementing modified versions of lifestyle 
interventions from clinical trials have been demonstrated to be effective in real-
world settings.
■ Government, public health and clinical sectors each have a critical role in 
preventing Type 2 diabetes by setting policies that promote healthy nutritional and 
agricultural policies, favor modifications in the environment that encourage greater 
physical activity and by identifying and referring individuals at high risk to 
affordable, accredited intervention programs.
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Figure 1. Prevention of Type 2 diabetes: the community–civic partnership model
Provided by CDC, Division of Diabetes Translation. Elements in the clinical component are 
adapted from the Chronic Care Model, MacColl Institute for Healthcare Innovation. The 
elements listed in this figure are not intended to be all-inclusive, but to provide information 
on the kinds of elements contributed by each sector and shared across sectors.
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